Results 31 to 40 of about 2,071 (176)
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials [PDF]
, 2023 Objectives: Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations, for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) and BE MOBILE 2 (radiographic axSpA (r-axSpA)) are double-blind, phase ...Tomita, T., Maksymowych, Walter P, Marina Magrey, Hiroaki Dobashi, Van den Bosch, Filip, Marga Oortgiesen, Magrey, Marina, Baraliakos, Xenofon, Julie Shepherd-Smith, Fleurinck, C., Bosch, F. van den, Dougados, Maxime, Brown, Matthew A., Xenofon Baraliakos, Shepherd-Smith, Julie, Matthew A Brown, Gaffney, K., Gensler, Lianne S, Nigil Haroon, Rudwaleit, Martin, Baraliakos, X., Karl Gaffney, Ute Massow, Lianne S Gensler, Oortgiesen, M., Atul Deodhar, Maksymowych, Walter P., Brown, M.A., Magrey, M., Heijde, D. van der, Haroon, N., Dobashi, Hiroaki, Marten, A., Fleurinck, Carmen, Gensler, Lianne S., Dougados, M., Shepherd-Smith, J., Xu, H.J., Vaux, T., Maksymowych, W.P., Alicia M Ellis, Marten, Alexander, Ellis, A.M., Rudwaleit, M., Oortgiesen, Marga, Massow, U., Denis Poddubnyy, Walter P Maksymowych, Filip Van den Bosch, Gaffney, Karl, Martin Rudwaleit, Deodhar, Atul, Désirée van der Heijde, Maxime Dougados, Poddubnyy, D., Gensler, L.S., Elewaut, D., Xu, Huji, Deodhar, A., van der Heijde, Desiree, Ellis, Alicia M., Tetsuya Tomita, Ellis, Alicia M, Alexander Marten, Massow, Ute, Dirk Elewaut, Haroon, Nigil, Poddubnyy, Denis, Brown, Matthew A, Dobashi, H., Thomas Vaux, Elewaut, Dirk, Carmen Fleurinck, Huji Xu, Tomita, Tetsuya, Vaux, Thomas +75 morecore +1 more sourceBimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. [PDF]
Rheumatology (Oxford)Objectives Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and clinical efficacy in patients with psoriatic arthritis (PsA). Here, we report an additional year of Gossec L, Coates LC, Landewé RBM, Mease PJ, Merola JF, Ritchlin CT, Tanaka Y, Asahina A, Proft F, Goldammer N, Manente M, Ink B, Bajracharya R, Coarse J, McInnes IB. +14 moreeuropepmc +2 more sourcesEffectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
Frontiers in Medicine, 2023 IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis.Luigi Gargiulo, Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, Antonio Costanzo, Antonio Costanzo +46 moredoaj +1 more sourceRisk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database
Arthritis &Rheumatology, EarlyView.Objective
To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods
This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas +7 morewiley +1 more sourceImpact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension
Arthritis &Rheumatology, Accepted Article.Objectives
To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G.W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard +10 morewiley +1 more sourceBimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT
Dermatology and TherapyIntroduction While bimekizumab has demonstrated rapid, superior clinical efficacy versus adalimumab and ustekinumab, with sustained responses through 4 years, its comparative and long-term impact on patient-reported outcomes (PROs) remains underexplored. April Armstrong, Kim A. Papp, Mark Lebwohl, Laura J. Savage, Keiichi Yamanaka, Diana Elena Vlase, Rhys Warham, Jérémy Lambert, José M. López Pinto, Krista Wixted, Diamant Thaçi +10 moredoaj +1 more sourceEarly diagnosis of axial spondyloarthritis is associated with less long‐term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry
Arthritis &Rheumatology, Accepted Article.Objectives
The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration ≤2 years of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between early and established axSpA patients treated with biologic/targeted synthetic disease‐modifying anti ...Annik Steimer, Jonas Brändli, Mauro Bachmann, Andrea Götschi, Claudia L. Rodrigues, Michael J. Nissen, Burkhard Möller, Kristina Bürki, Martin Wendiggensen, Simon Grosswiler, Michael Andor, Diana Dan, Frauke Förger, Sabine Adler, Diego Kyburz, Oliver Distler, Raphael Micheroli, Sofia Ramiro, Adrian Ciurea +18 morewiley +1 more sourceCost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
, 2023 Aims: To evaluate the cost-effectiveness of bimekizumab, an inhibitor of IL-17F and IL-17A, against biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARD) for psoriatic arthritis (PsA) from the Swedish healthcare system perspective.Oldsberg, Linnea, Oldsberg, Linnea,, Willems, Damon, Willems, Damon,, Valgerdur Sigurdardottir, Engstrom, Anna,, Tor Olofsson, Berling, Patric, Melis, Lode, Sigurdardottir, Valgerdur, Devian Parra, Linnea Oldsberg, Patric Berling, Melis, Lode,, Sigurdardottir, Valgerdur,, Anna Engstrom, Olofsson, Tor, Sadler, Susannah,, Lode Melis, Engstrom, Anna, Parra-Padilla, Devian,, Parra-Padilla, Devian, Berling, Patric,, Olofsson, Tor,, Damon Willems, Susannah Sadler, Sadler, Susannah +26 morecore +2 more sourcesBimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years
Journal of Dermatological TreatmentObjectives To investigate the proportion of bimekizumab-treated patients achieving complete clearance in high-impact areas over a four-year period and concurrent patient-reported quality of life outcomes.Methods In this analysis, data are included from ...Paolo Gisondi, Boni Elewski, Andreas Pinter, Yukie Yamaguchi, Melinda Gooderham, Sarah Kavanagh, Krista Wixted, Nancy Cross, Balint Szilagyi, Joseph F. Merola +9 moredoaj +1 more source
